The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review

Arch Physiol Biochem. 2023 Jun;129(3):752-770. doi: 10.1080/13813455.2021.1871761. Epub 2021 Feb 11.

Abstract

Although the prevalence of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors that predispose to the development of type 2 diabetes mellitus and cardiovascular diseases, is increasing globally, there is no broad-spectrum agent for its holistic treatment. Natural plant-derived products with a wide spectrum of biological activities are currently being explored as alternatives in the management of diseases. Artemisia species are a heterozygous group of plants of the Compositae family that possess several health benefits. Here we highlight their antidiabetic, anti-obesity, anti-hyperlipidaemic, hepatoprotective and cardioprotective properties among others. These activities have been linked to the presence of phytochemicals that act on several molecular targets to exert their effects and the species of Artemisia are considered to be relatively safe. Artemisia species offer significant anti-MetS activity and thus are strong therapeutic candidates for the effective management of MetS.

Keywords: Artemisia; diabetes mellitus; metabolic syndrome; non-alcoholic fatty liver disease; obesity.

Publication types

  • Review

MeSH terms

  • Artemisia* / chemistry
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2* / etiology
  • Metabolic Syndrome* / drug therapy
  • Obesity / complications